Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Infinity Pharmaceuticals Inc INFIQ

Healthcare Biotechnology
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K... see more

Recent & Breaking News (GREY:INFIQ)

Infinity to Participate in Three Conferences in September

Business Wire September 2, 2015

Infinity Provides Company Update and Reports Second Quarter 2015 Financial Results

Business Wire August 6, 2015

Infinity Announces the Date of Its Second Quarter 2015 Financial Results Conference Call and Webcast

Business Wire July 30, 2015

Infinity to Participate in Two Upcoming Conferences

Business Wire July 21, 2015

Infinity Reports Phase 1 Data Showing Clinical Activity of Duvelisib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Business Wire May 31, 2015

Infinity to Participate in Three Investor Conferences in June

Business Wire May 27, 2015

Infinity Reports Preclinical Data for Duvelisib Demonstrating Synergy with Standard-of-Care Therapies and Emerging Agents in Development for the Treatment of Hematologic Malignancies

Business Wire May 26, 2015

Infinity Announces New Data for Duvelisib to Be Presented at the 2015 American Society of Clinical Oncology Annual Meeting

Business Wire May 13, 2015

Infinity Reports First Quarter 2015 Financial Results and Recent Corporate Developments

Business Wire May 6, 2015

Infinity to Participate in Three Conferences in May

Business Wire April 30, 2015

Infinity Announces the Date of Its First Quarter 2015 Financial Results Conference Call and Webcast

Business Wire April 22, 2015

Infinity Reports Preclinical Data for Duvelisib in Combination with Venetoclax at the 2015 American Association for Cancer Research Annual Meeting

Business Wire April 20, 2015

Infinity Augments Executive Leadership Team, Appointing Chief Commercial Officer and General Counsel

Business Wire April 14, 2015

Infinity Provides Company Update and Reports Full-Year 2014 Financial Results

Business Wire February 24, 2015

Infinity to Present at the RBC Capital Markets 2015 Healthcare Conference

Business Wire February 18, 2015

Infinity Announces the Date of Its Full-Year 2014 Financial Results Conference Call and Webcast

Business Wire February 10, 2015

Infinity Provides Key 2015 Goals and Financial Guidance

Business Wire January 12, 2015

Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis

Business Wire January 8, 2015

Infinity to Present at J.P. Morgan 33rd Annual Healthcare Conference

Business Wire January 5, 2015

Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at the American Society of Hematology Annual Meeting

Business Wire December 9, 2014